Gilead Sciences (GILD) Downgraded by Argus

Gilead Sciences (NASDAQ:GILD) was downgraded by equities researchers at Argus from a “buy” rating to a “hold” rating in a research report issued on Monday, November 13th, Marketbeat.com reports. They currently have a $73.77 target price on the biopharmaceutical company’s stock, up from their prior target price of $73.25. Argus’ price objective indicates a potential downside of 2.08% from the company’s previous close.

Several other research analysts have also recently weighed in on GILD. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Monday, July 17th. BMO Capital Markets reaffirmed a “hold” rating and set a $72.00 target price on shares of Gilead Sciences in a report on Friday, July 21st. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Leerink Swann restated a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 25th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $85.22.

Gilead Sciences (NASDAQ GILD) opened at $75.34 on Monday. The stock has a market cap of $97,682.80, a P/E ratio of 7.81, a PEG ratio of -1.25 and a beta of 1.14. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the company earned $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts forecast that Gilead Sciences will post 8.53 EPS for the current year.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders sold a total of 458,486 shares of company stock worth $35,190,731 in the last ninety days. 1.30% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in GILD. Welch Investments LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth approximately $108,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares in the last quarter. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences in the 3rd quarter worth approximately $133,000. Finally, American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $143,000. Institutional investors and hedge funds own 76.23% of the company’s stock.

WARNING: This article was reported by BBNS and is owned by of BBNS. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-downgraded-to-hold-at-argus/1781778.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.